期刊文献+

外周血单核细胞数量与肺癌放疗近、远期疗效的相关性分析 被引量:7

Correlation analysis between peripheral blood mononuclear cells and radiotherapy effect in lung cancer
原文传递
导出
摘要 目的基于外周血单核细胞(pbMXD)迁徙在肿瘤放疗后复发中的重要作用,探讨pbMXD在监测肺癌放疗近、远期疗效中的价值。方法回顾性分析肺癌放疗患者,随访观察其放疗前后血象变化、pbMXD变化与近、远期疗效的相关性。结果105例肺癌患者,整体客观缓解率(RR)61.9%(65/105),中位无进展生存期(PFS)5.0个月(1~20.3个月);28例局部晚期非小细胞肺癌(NSCLC),同步放化疗组RR为66.7%(8/12),PFS6.5个月(1.5—14.2个月)。两类资料中,放疗前、后pbMXD绝对值、相对值及变化值与RR和PFS均无显著相关性(P〉0.05);pbMXD最低值与整体NSCLC和局部晚期NSCLC单纯放疗组的近期疗效相关(P〈0.05)。结论NSCLC放疗中,pbMXD最低值对预判近期疗效有一定价值,阻断pbMXD迁徙或有较好临床前景。 Objective Based on the migration of peripheral blood mononuclear cells (pbMXD) plays an important role in tumor recurrence after radiotherapy, we further study its value in monitoring lung cancer radiotherapy effect. Methods Retrospective analysis the routine blood before and after radiotherapy in lung cancer, observe the correlation between pbMXD and short, long-term curative effect. Results The overall radiation effective rate (RR) was 61.9%, and the median progression-free surial (PFS) was 5 months (1- 20.3 months) in 105 lung cancer cases. In the 28 cases of locally advanced NSCLC, the RR was 66.7%, and the median PFS was 6.5 months ( 1.5-14.2 months) in the concurrent chemoradiotherapy group. There has no significant correlation between absolute, relative and changing values of pbMXD with RR or PFS (P 〉 0. 05 ). The minimum pbMXD has correlation with overall NSCLC and locally advanced NSCLC in simple radiotherapy group (P 〈 0. 05 ). Conclusions In NSCLC radiotherapy, the minimum pbMXD has a certain value in monitoring short-term effect, and block the migration of pbMXD or has a good clinical prospect.
出处 《中华肺部疾病杂志(电子版)》 CAS 2014年第2期29-33,共5页 Chinese Journal of Lung Diseases(Electronic Edition)
基金 国家自然科学基金资助项目(81272496) 重庆市自然科学基金(cstc2012jjB0076) 第三军医大学校管课题(2011D264)
关键词 支气管肺癌 外周血单核细胞 放射治疗 疗效分析 预后 Bronchogenic carcinoma Peripheral blood mononuclear cell Radiation therapy Effect Prognosis
  • 相关文献

参考文献18

  • 1Jemal A, Bray F, Center MM, et al. Global cancer statistics [ J ]. CA Cancer J Clin, 2011, 61(2) : 69-90.
  • 2Tyldesley S, Boyd C, Schulze K, et al. Estimating the need for radiotherapy for lung cancer: an evidence-based, epidemiologic approach [J]. Int J Radiat Oncol Biol Phys, 2001, 49(4) : 973- 985.
  • 3邹晶,徐兴祥,王大新,钱桂生.肺癌放化疗“实时”疗效评估方法的研究进展[J].中华肺部疾病杂志(电子版),2013,6(4):60-63. 被引量:6
  • 4Socha J, Kolodziejczyk M, Kpka L. Outcome after PET-CT based radiotherapy for non-small cell lung cancer [ J]. Pneumonol Alergol Pol, 2013, 81(1): 30-39.
  • 5Osti MF, Agolli L, Valeriani M, et al. Image guided hypofractionated 3-dimensianal radiation therapy in patients with inoperable advanced stage non-small cell lung cancer [ J]. Int J Radiat Oncol Biol Phys, 2013, 85(3) : e157-163.
  • 6Kioi M, Vogel H, Schultz G, et al. Inhibition of vasculogenesis, but not angiogenesis, prevents the recurrence of glioblastoma after irradiation in mice [J]. J CIin Invest, 2010, 120(3) : 694-705.
  • 7Ahn GO, Brown JM. Matrix metalloproteinase-9 is required for tumor vasculogenesis but not for angiogenesis : role of bone marrow-derived myelomonocytic ceils [J]. Cancer Cell, 2008, 13(3) : 193-205.
  • 8Chen FI-I, Chiang C,S, Wang CC, et al. Radiotherapy decreases vascular density and causes hypoxia with maerophage aggregation in TRAMP- C1 prostate tumors [ J]. Clin Cancer Res, 2009, 15 (5) : 1721- 1729.
  • 9Priceman SJ, Sung JL, Shaposhnik Z, et al. Targeting distinct tumor- infiltrating myeloid cells by inhibiting CSF-1 receptor: combatingtumor evasion of antiangiogenic therapy [J]. Blood, 2010, 115 (7) : 1461-1471.
  • 10Tang DG, Conti CJ. Endothelial cell development, vasculogenesis, angiogenesis, and tumor neovascularization : an update [ J ]. Semin Thromb Hemost, 2004, 30( 1 ) : 109-117.

二级参考文献44

  • 1Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012[ J]. CA Cancer J Clin, 2012, 62(1) :10-29.
  • 2Hallqvist A, Bergman B, Nyman J. Health related quality of life in locally advanced NSCLC treated with high dose radiotherapy and concurrent chemotherapy or cetuximab-pooled results from two prospective clinical trials [ J ]. Radiother Oncol, 2012, 104 ( 1 ) :3944.
  • 3Ganguli A, Wiegand P, Gao X, et al. The impact of second-line agents on patients' health-related quality of life in the treatment for non-small cell lung cancer: a systematic review [ J]. Qual Life Res, 2013, 22(5) : 1015-1026.
  • 4石远凯,李峻岭,吴昌归,等.亚太地区含泰索帝方案一线治疗晚期非小细胞肺癌(NSCLC)患者生活质量(QOL)评估及与缓解率相关性的多中心Ⅲ期临床研究:中国患者亚组中期总结[C].第三届中国肿瘤内科大会教育集暨论文集.北京.中国协和医科大学出版社,2009.478-480.
  • 5Saad ED, Adamowicz K, Katz A, et al. Assessment of quality of life in advanced non-small-cell lung cancer: an overview of recent randomized trials [ J ]. Cancer Treat Rev, 2012, 38 (6) : 807-814.
  • 6Soussan M, Chouahnia K, Maisonobe JA, et al. Prognostic implications of volume-based measurements on FDG PET/CT in stage m non- small-cell lung cancer after induction chemotherapy [ J ]. Eur J Nucl Med Mol Imaging, 2013, 40(5) : 6684576.
  • 7Skoura E, Datseris IE, Platis I, et al. Role of positron emission tomography in the early prediction of response to chemotherapy in patients with non-small-cell lung cancer [ J]. Clin Lung Cancer, 2012, 13(3) :181-187.
  • 8Dahele M, Freeman M, Pearson S, et al. Early metabolic response evaluation after stereotactic radiotherapy for lung cancer: pilot experience with 18 F-fluorodeoxyglucose positron emission tomography-computed tomography [ J ]. Clin Oncol (R Coll Radiol), 2011, 23(5): 359-363.
  • 9Saga T, Koizumi M, Inubushi M, et al. PET/CT with 3'-deoxy- 3' -[ 18F] fluorothymidine for lung cancer patients receiving carbon- ion radiotherapy[ J ]. Nucl Med Commun, 2011, 32 (5) : 348-355.
  • 10de Langen A J, van den Boogaart V, Lubberink M, et al. Monitoring response to antiangiogenic therapy in non-small cell lung cancer using imaging markers derived from PET and dynamic contrast- enhanced MRI [J]. J Nucl Med, 2011, 52(1) : 48-55.

共引文献11

同被引文献49

  • 1赵跃,郭永刚,孙甲甲,刘春蓉,周广磊,黄景昊,王宁,吴凤云.术前SII、NLR、PLR在分化型甲状腺癌中的诊断价值分析[J].兰州大学学报(医学版),2018,0(6):50-56. 被引量:9
  • 2李艳华,韩素桂.放疗化疗对恶性肿瘤患者外周血细胞形态的影响[J].疑难病杂志,2004,3(4):243-243. 被引量:5
  • 3李树玲.乳腺癌防治研究现状[J].国外医学(肿瘤学分册),1993,20(4):221-226. 被引量:28
  • 4Jemal A, Bray F, Center MM, et al. Global cancer statistics [ J ]. CA Cancer J Clin, 2011, 61(2) : 69-90.
  • 5Tyldesley S, Boyd C, Schulze K, et al. Estimating the need for radiotherapy for lung cancer: an evidence-based, epidemiologic approach [J]. Int J Radiat Oncol Biol Phys, 2001, 49(4) : 973- 985.
  • 6Socha J, Kolodziejczyk M, Kpka L. Outcome after PET-CT based radiotherapy for non-small cell lung cancer [ J]. Pneumonol Alergol Pol, 2013, 81(1): 30-39.
  • 7Osti MF, Agolli L, Valeriani M, et al. Image guided hypofractionated 3-dimensianal radiation therapy in patients with inoperable advanced stage non-small cell lung cancer [ J]. Int J Radiat Oncol Biol Phys, 2013, 85(3) : e157-163.
  • 8Kioi M, Vogel H, Schultz G, et al. Inhibition of vasculogenesis, but not angiogenesis, prevents the recurrence of glioblastoma after irradiation in mice [J]. J CIin Invest, 2010, 120(3) : 694-705.
  • 9Ahn GO, Brown JM. Matrix metalloproteinase-9 is required for tumor vasculogenesis but not for angiogenesis : role of bone marrow-derived myelomonocytic ceils [J]. Cancer Cell, 2008, 13(3) : 193-205.
  • 10Chen FI-I, Chiang C,S, Wang CC, et al. Radiotherapy decreases vascular density and causes hypoxia with maerophage aggregation in TRAMP- C1 prostate tumors [ J]. Clin Cancer Res, 2009, 15 (5) : 1721- 1729.

引证文献7

二级引证文献47

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部